Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 19/20 | 0.49 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4154806 | 1.00 | ERBB2 (0.49) | ERBB2MINK1BCHEACHEBACE1 | |
| SCHEMBL4506953 | 0.87 | ERBB2 (0.49) | ERBB2MINK1 | |
| SCHEMBL4506956 | 0.87 | ERBB2 (0.49) | ERBB2MINK1 | |
| SCHEMBL3075346 | 0.82 | ERBB2 (0.67) | ERBB2 | |
| SCHEMBL3075344 | 0.82 | ERBB2 (0.67) | ERBB2 | |
| SCHEMBL5557716 | 0.78 | PIM1 (0.41) | ERBB2BCHEACHEBACE1 | |
| SCHEMBL5557711 | 0.78 | PIM1 (0.41) | ERBB2BCHEACHEBACE1 | |
| SCHEMBL4159387 | 0.77 | ERBB2 (0.55) | ERBB2 | |
| SCHEMBL4159385 | 0.77 | ERBB2 (0.55) | ERBB2 | |
| SCHEMBL5761845 | 0.77 | ERBB2 (0.53) | ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093491-A1 | Diazine Azole Derivatives, Their Manufacture and Use as Pharmaceutical | JENNI WOLFGANG | 2009-04-09 | — | — | US | disclosed |
| EP-1934210-A1 | DIAZINE AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039226-A1 | DIAZINE AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| EP-1758897-A1 | NOVEL DIAZINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-07 | — | — | EP | disclosed |
| US-7179812-B2 | Diazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-02-20 | — | — | US | disclosed |
| WO-2005097785-A1 | NOVEL DIAZINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-10-20 | — | — | WO | disclosed |
| US-20050222228-A1 | Novel diazine derivatives | HOFFMANN-LA ROCHE INC. | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222228-A1 | Novel diazine derivatives | BRCA1, SLC5A1, PDHA1 | ERBB2 1298/4885MINK1 749/4885BCHE 443/4885 |
| US-20090093491-A1 | Diazine Azole Derivatives, Their Manufacture and Use as Pharmaceutical | CYP3A5, CYP3A7, CYP3A43 | ERBB2 1997/4885MINK1 807/4885BCHE 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.